Skip to main content

Vivimusta Injection Dosage

Generic name: BENDAMUSTINE HYDROCHLORIDE 25mg in 1mL
Dosage form: injection
Drug class: Alkylating agents

Medically reviewed by Drugs.com. Last updated on Dec 7, 2022.

Dosing Instructions for CLL

Recommended Dosage
The recommended dosage is 100 mg/m2 administered intravenously over 20 minutes on Days 1 and 2 of a 28-day cycle for up to 6 cycles.

Dose Delays, Dose Modifications and Re-initiation of Therapy for CLL
Delay VIVIMUSTA for Grade 4 hematologic toxicity or clinically significant Grade 2 or greater non-hematologic toxicity.

Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) greater than or equal to 1 x 109/L and platelets greater than or equal to 75 x 109/L], reinitiate VIVIMUSTA at the discretion of the healthcare provider. In addition, consider dose reduction [see Warnings and Precautions (5.1)]

Dose modifications for hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 50 mg/m2 on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m2 on Days 1 and 2 of each cycle.

Dose modifications for non-hematologic toxicity: for clinically significant Grade 3 or greater toxicity, reduce the dose to 50 mg/m2 on Days 1 and 2 of each cycle.

Consider dose re-escalation in subsequent cycles at the discretion of the healthcare provider.

Dosing Instructions for NHL

Recommended Dosage
The recommended dosage is 120 mg/m2 administered intravenously over 20 minutes on Days 1 and 2 of a 21-day cycle for up to 8 cycles.

Dose Delays, Dose Modifications and Re-initiation of Therapy for NHL
Delay VIVIMUSTA for Grade 4 hematologic toxicity or clinically significant Grade 2 or greater non-hematologic toxicity.

Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) greater than or equal to 1 x 109/L and platelets greater than or equal to 75 x 109/L], reinitiate VIVIMUSTA at the discretion of the healthcare provider. In addition, consider dose reduction [see Warnings and Precautions (5.1)]

Dose modifications for hematologic toxicity: for Grade 4 toxicity, reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle; if Grade 4 toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.

Dose modifications for non-hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.

Preparation and Administration


VIVIMUSTA is a hazardous drug. Follow applicable special handling and disposal procedures.1


VIVIMUSTA is a clear and colorless to yellow solution in a multiple-dose vial.

Store VIVIMUSTA refrigerated at 2°C to 8°C (36°F to 46°F). When refrigerated, the contents may partially freeze. Allow the vial to reach room temperature (15°C to 30°C or 59°F to 86°F) prior to use. Observe the contents of the vial for any visible solid or particulate matter. Do not use the product if solid or particulate matter is observed after reaching room temperature.



Intravenous Infusion

Aseptically withdraw the volume needed for the required dose from the 25 mg/mL solution as per Table 1 below and immediately transfer to a 250 mL infusion bag of one of the following diluents: 0.9% Sodium Chloride Injection, USP; or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP.

The resulting final concentration of bendamustine hydrochloride in the infusion bag should be within 0.1 mg/mL to 1.36 mg/mL.

After transferring, thoroughly mix the contents of the infusion bag. The admixture should be a clear and colorless to slightly yellow solution.


No other diluents have been shown to be compatible [see Dosage and Administration (2.4)].


Table 1: Volume of VIVIMUSTA required for Dilution into 250 mL of 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP for a Given Dose and Body Surface Area


Body Surface Area (m2)
 Volume of VIVIMUSTA to Withdraw (mL) from Vial
120 mg/m2
 100 mg/m2
 90 mg/m2
 60 mg/m2
 50 mg/m2
 25 mg/m2
1
 4.8
 4
 3.6
 2.4
 2
 1
1.1
 5.3
 4.4
 4
 2.6
 2.2
 1.1
1.2
 5.8
 4.8
 4.3
 2.9
 2.4
 1.2
1.3
 6.2
 5.2
 4.7
 3.1
 2.6
 1.3
1.4
 6.7
 5.6
 5
 3.4
 2.8
 1.4
1.5
 7.2
 6
 5.4
 3.6
 3
 1.5
1.6
 7.7
 6.4
 5.8
 3.8
 3.2
 1.6
1.7
 8.2
 6.8
 6.1
 4.1
 3.4
 1.7
1.8
 8.6
 7.2
 6.5
 4.3
 3.6
 1.8
1.9
 9.1
 7.6
 6.8
 4.6
 3.8
 1.9
2
 9.6
 8
 7.2
 4.8
 4
 2
2.1
 10.1
 8.4
 7.6
 5
 4.2
 2.1
2.2
 10.6
 8.8
 7.9
 5.3
 4.4
 2.2
2.3
 11
 9.2
 8.3
 5.5
 4.6
 2.3
2.4
 11.5
 9.6
 8.6
 5.8
 4.8
 2.4
2.5
 12
 10
 9
 6
 5
 2.5
2.6
 12.5
 10.4
 9.4
 6.2
 5.2
 2.6
2.7
 13
 10.8
 9.7
 6.5
 5.4
 2.7
2.8
 13.4
 11.2
 10.1
 6.7
 5.6
 2.8
2.9
 13.9
 11.6
 10.4
 7
 5.8
 2.9
3
 14.4
 12
 10.8
 7.2
 6
 3

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Discard any unused solution according to institutional procedures for hazardous drugs.

Admixture Stability

VIVIMUSTA contains no antimicrobial preservative. Prepare the admixture as close as possible to the time of patient administration.

Once diluted with 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, the final admixture is stable for 24 hours when stored refrigerated conditions (2°C to 8°C or 36°F to 46°F) or for 3 hours when stored at room temperature (15°C to 30°C or 59°F to 86°F) and room light. Complete administration of diluted VIVIMUSTA within this period of time.

VIVIMUSTA (bendamustine hydrochloride injection) is supplied in a multiple-dose vial. Retain the partially used vial in original package to protect from light and store refrigerated (2°C to 8°C or 36°F to 46°F) if additional dose withdrawal from the same vial is intended.

Stability of Partially Used Vials (Needle Punched Vials)

VIVIMUSTA is supplied as a multiple-dose vial. Although it does not contain any antimicrobial preservative, VIVIMUSTA is bacteriostatic. The partially used vials are stable for up to 28 days when stored in its original carton under refrigeration (2°C to 8°C or 36°F to 46°F). Each vial is not recommended for more than a total of six (6) dose withdrawals.

After first use, store the partially used vial in the original carton at 2°C to 8°C (36°F to 46°F) and then discard after 28 days.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer